Effects of rosglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and type 2 diabetes

Metabolism: Clinical and Experimental

Volumn 53, Issue 12, 2004, Pages 1552-1557

  Osei, Kwame ^a,c   Gaillard, Trudy ^a   Kaplow, June ^b   Bullock, Matthew ^b   Schuster, Dara ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b PENNSYLVANIA HOSPITAL   (United States)

^c FACE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C PEPTIDE; GLUCOSE; INSULIN; ROSIGLITAZONE;

ADULT; AFRICAN AMERICAN; ARTICLE; CELL SECRETION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; HIGH RISK POPULATION; HOMEOSTASIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MATHEMATICAL COMPUTING; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

ADIPONECTIN; ADULT; AFRICAN AMERICANS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; ISLETS OF LANGERHANS; LIPIDS; LONGITUDINAL STUDIES; MIDDLE AGED; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 9344257284     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2004.06.023     Document Type: Article

References (41)

1. DeFronzo R.A. The triumvirate, B-cell, muscle, liver A collusion responsible for NIDDM. Diabetes. 37:1988;667-687
2. Osei K., Gaillard T., Schuster D. Pathogenetic mechanism of impaired glucose tolerance and type 11 diabetes in African Americans The significance of insulin secretion, insulin sensitivity and glucose effectiveness. Diabetes Care. 20:1997;396-404
3. Vaag A., Henrikson J.E., Madsbad S., et al. Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin dependent mellitus. J Clin Invest. 95:1995;690-698
4. Phillips S.A., Ciaraldi T.P., Kong A.P.S., et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes. 52:2003;667-674
5. Peline F., Smith U., Funahashi T., et al. Circulating adiponectin levels are reduced in nonobese but insulin resistant first-degree relatives of type 2 diabetic patients. Diabetes. 52:2003;. 1182-1166
6. Lihn A.S., Ostergard T., Nyholm B., et al. Adiponectin expression in adipose tissue is reduced in first-degree relatives of type 2 diabetic patients. Am J Physiol. 284:2003;443-452
7. Krakoff J., Funahaser T., Stenhouwer C.D.A., et al. Inflammatory markers, adiponectin and the risk of type 2 diabetes in the Pima Indians. Diabetes Care. 26:2003;1745-1751
8. Weyer C., Funahashi T., Tanaka S., et al. Hypoadiponectinemia in obesity and type 2 diabetes Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 86:2001;1930-1935
9. Lindsay R.S., Funahasha T., Hansen R.I., et al. Adiponectin protects against development of type 2 diabetes in Pima Indian population. Lancet. 360:2002;57-58
10. Sprangler J., Kroke A., Mohlig M., et al. Adiponectin and protection against type 2 diabetes. Lancet. 361:2003;226-228
11. Cnop M., Havel P.J., Ultzchneider K.M., et al. Relationship of adiponectin to body fat distribution: Insulin sensitivity and plasma lipoproteins: Evidence for independent roles of age and sex. Diabetologia. 46:2003;459-469
12. Yannakoulia M., Yiannkouris N., Bluher S., et al. Body fat mass and macronutrient intake in relationship to circulating soluble leptin receptor, free leptin index, adiponectin and resistin concentrations in healthy humans. J Clinical Endocrinol Metab. 88:2003;1730-1736
13. Yamauchi T., Kamon J., Waki H., et al. The fat derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 7:2001;941-946
14. Stefan N., Vozarova B., Funabashi Y., et al. Plasma adiponectin levels are not associated with fat oxidation in humans. Obes Res. 10:2002;1016-1020
15. Yu J.G., Javorschi S., Hevener A.L., et al. The effect of thiazoldinediones on plasma adiponectin levels in normal, obese and type 2 diabetes. Diabetes. 51:2002;2968-2974
16. Brunn J.M., Lihn A.S., Verdich C., et al. Regulation of adiponectin by adipose tissue derived adipcytokines In vivo and in vitro investigations in humans. Am J Physiol. 285:2003;E527-533
17. Maeda A., Takashiko M., Funshashi T., et al. PPARy increase expression and plasma concentrations of adiponectin, adipose-derived protein. Diabetes. 50:2001;2094-2099
18. Moshima H., Wu X., Sinha M., et al. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes Effects of insulin and rosiglitazone. J Clin Endocrinol Metab. 87:2002;5662-5667
19. Moore G.B.T., Chapman H., Holder J.C., et al. Differential regulation of adipocytokine mRNAs by rosiglitazone in db/db mice. Biochem Biophys Res Commun. 286:2001;735-741
20. Maeda N., Takahashi M., Funahashi T., et al. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 50:2001;2094-2099
21. Kumada M., Kihara S., Sumitsuji S., et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vas Biol. 23:2003;85-89
22. Moshima H., Wu X., Sinha M., et al. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes Effects of insulin and rosiglitazone. J Clin Endocrinol Metab. 87:2002;5662-5667
23. Ouchi N., Kumada M., Kihara S., et al. Novel modulator for endothelial adhesion molecules Adipocyte-derived plasma protein adiponectin. Circulation. 100:1999;2473-2476
24. Saghizadeh M., Ong J.M., Garvey W.T., et al. The expression of TNF-a by human muscle Relationship to insulin resistance. J Clin Invest. 97:1996;1111-1116
25. Straczkowski M.A., Kowalska I., Stepien A., et al. Plasma-soluble tumor necrosis factor alpha-receptors level in lean, nondiabetic offspring of type 2 diabetic subjects. Diabetes Care. 25:2002;1824-1828
26. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor alpha Direct role in obesity linked insulin resistance. Science. 259:1993;87-91
27. Kern P.A., Saghisadeh M., Ong J.M., et al. The expression of tumor necrosis in human adipose tissue Regulation by obesity, weight, loss and relationship to lipoprotein lipase. J Clin Invest. 95:1995;211-219
28. Fernandez-Real J.-M., Ricart W. Insulin resistance and inflammation in an evolutionary perspective the contribution of cytokine genotype/phenotype to thriftiness. Diabetologia. 42:1999;1367-1374
29. Hulver M.W., Saleh O., MacDonald K.G., et al. Ethnic differences in adiponectin levels. Metabolism. 53:2004;1-3
30. Yang W.-S., Lee W.-J., Funahashi T., et al. Plasma adiponectin levels in overweight and obese Asians. Obes Res. 10:2002;1104-1110
31. Osei K., Schuster D.P. Ethnic differences in secretion, sensitivity and hepatic extraction of insulin in black and white Americans. Diabet Med. 11:1994;755-762
32. Arslanian S., Suprasongsin C. Differences in the in vivo insulin secretion and sensitivity in healthy blacks versus white adolescents. J Pediatr. 129:1996;440-443
33. Goran M.I., Crutz M.L., Bergman R.N., et al. Insulin resistance and associated compensatory responses in African American and Hispanic children. Diabetes Care. 25:2002;2184-2190
34. Srinivisan S.R., Myers L., Berenson G.S. Predictability of childhood adiposity and insulin for developing insulin resistance syndrome (Syndrome X) in young adulthood The Bogalusa Heart Study. Diabetes. 51:2002;204-209
35. Osei K., Cottrell D.A. Minimal model analyses of insulin sensitivity and glucose dependent glucose disposal in black and white Americans A study of persons at risk for type 2 diabetes. Eur J Clin Invest. 24:1994;843-850
36. Renynolds L.R., Konz E.C., Frederich R.G., et al. Rosiglitazone amplifies the benefits lifestyle intervention measures in long-term, type 2 diabetes mellitus. Diabetes Obes Metab. 4:2002;270-275
37. Buchanan T.A. Pancreatic beta cell defects in gestational diabetes Implications for the pathogenesis and prevention of type 2 diabetes. J Clin Endocrinol Metab. 86:2001;989-993
38. Buchanan T.A., Xiang A.H., Peters R.K., et al. Preservation of pancreatic beta cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high risk Hispanic women. Diabetes. 51:2002;2796-2803
39. Schuster D., Gaillard T., Rhinesmith S., et al. The impact of an insulin sensitizer, troglitazone, on glucose metabolism in African Americans at risk for type 2 diabetes A placebo-controlled, 24-month randomized study. Metabolism. 52:2003;1211-1217
40. The Expert Committee on the Diagnosis of Diabetes Mellitus. Diabetes Care. 20:1997;1183-1197
41. Mathews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28:1985;412-419